Patrick Soon‐Shiong, MD, FRCS, FACS

//Patrick Soon‐Shiong, MD, FRCS, FACS

Patrick Soon‐Shiong, MD, FRCS, FACS

Dr. Soon-Shiong a physician, surgeon and scientist, has pioneered novel therapies for both diabetes and cancer, published more than 100 scientific papers, and has more than 170 issued patents worldwide on groundbreaking advancements spanning myriad fields of technology and medicine.

Dr. Soon-Shiong serves as Chairman of the Chan Soon-Shiong Family Foundation, Chairman and CEO of the Chan Soon-Shiong Institute of Molecular Medicine, a non-profit medical research organization and Chairman and CEO of NantKwest, a NASDAQ listed immunotherapy company focusing on Natural Killer cells. He currently co-chairs the CEO Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America. He is an Adjunct Professor of Surgery at UCLA, and a visiting Professor at the Imperial College of London and Dartmouth College. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award.

In 2016 Dr. Soon-Shiong launched Cancer MoonShot 2020, a coalition of biotech, pharma, academia, community oncologists, payers and government agencies committed to accelerating next generation sequencing, proteomics, big data analytics and immunotherapy drug.

Dr. Soon-Shiong performed the world’s first encapsulated human islet transplant, the first engineered islet cell transplant and the first pig to man islet cell transplant in diabetic patients. He invented and developed Abraxane, the nation’s first FDA approved protein nanoparticle albumin-bound delivery technology for the treatment of cancer. Abraxane was approved by the FDA for metastatic breast cancer in 2005, lung cancer in 2012, and pancreatic cancer in 2013. The drug is approved in the U.S. and E.U. for metastatic breast cancer, lung cancer and advanced pancreatic cancer, making it the only drug of its kind to be approved in first line therapies across this broad spectrum of tumors in both the US and EU.

From 1997 to 2010 Dr. Soon-Shiong has served as founder, Chairman and CEO of two global pharmaceutical companies, American Pharmaceutical Partners and Abraxis BioScience. Both were acquired for multibillion dollars in 2008 and 2010. In 2011 he founded NantWorks, an ecosystem of companies to create a transformative global health information and next generation pharmaceutical development network. In 2015 he initiated the public offering of NantKwest, setting a record when trading opened on NASDAQ as the largest biotech IPO by market cap in history